Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,037 shares of the specialty pharmaceutical company’s stock after selling 230 shares during the period. NewEdge Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $128,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth $25,000. Quadrant Capital Group LLC increased its stake in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 101 shares in the last quarter. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $28,000. Allianz SE acquired a new stake in Jazz Pharmaceuticals in the 4th quarter worth about $29,000. Finally, Jones Financial Companies Lllp increased its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on JAZZ. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Royal Bank of Canada reduced their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Morgan Stanley restated an “overweight” rating and set a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Finally, UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 over the last 90 days. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $120.05 on Friday. The firm has a market cap of $7.40 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The business’s fifty day simple moving average is $122.63 and its 200-day simple moving average is $122.42.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.